PureTech Health plc

NASDAQ:PRTC

Biotechnology

Healthcare
$17.38 +2.64%

+$0.45 today

Market cap
$423.09M
Beta
0.79
P/E (TTM)
-0.4
EPS (TTM)
-$45.37
52W Low $14.50High $19.92

Volume 0.01M

Average 0.01M

Financial health

PureTech Health plc financial health

Start with the overall verdict and the rule-based risk checks for PRTC, then work through liquidity, debt, balance-sheet quality, and claims on cash.

Financial health snapshot

Resilient

Debt service and balance sheet cushion look healthy, even if some working-capital ratios deserve context.

Cash and investments cover debt Healthy short-term liquidity Moderate leverage

Cash & Investments

$496.32M

Debt Cushion

$476.56M

Current Ratio

6.6x

Interest Coverage

N/A

Risk checks

3 of 10 flagged

  • Interest covered

    -2.2×

    Passes when: Operating income is at least 1.5× interest expense

  • Debt repayable from cash flow

    Negative FCF

    Passes when: Free cash flow could repay all debt within 5 years

  • Stable Altman Z-Score

    1.56 → 0.25

    Passes when: Z-Score is not falling while below the 2.99 safe zone

  • Positive equity

    Positive

    Passes when: Shareholders' equity is above zero

  • Short-term liquidity

    6.6×

    Passes when: Current assets are at least 1× current liabilities

  • Near-term debt covered

    56.7×

    Passes when: Cash and short-term investments cover debt due within 12 months

  • Manageable net debt

    Net cash

    Passes when: Net debt is below 3× EBITDA

  • Debt growth in line with sales

    -25.0% vs 30.6%

    Passes when: 3-year debt growth is no more than 5 points above revenue growth

  • Tangible equity base

    0.2%

    Passes when: Goodwill and intangibles are below 50% of equity

  • Limited dilution

    -39.3%/yr

    Passes when: Diluted share count grows less than 2% a year

Financial strength scores

How strong are the fundamentals over time?

Piotroski tests profitability, balance-sheet direction, and efficiency; Altman estimates bankruptcy risk. Compare the current scores with their fiscal-year history.

Financial strength scores

Piotroski F-Score and Altman Z-Score from the latest reported financials

No financial scores available.

Score history

Piotroski F-Score and Altman Z-Score recalculated from each fiscal year's statements and year-end market value.

Piotroski: 8–9 strong, 4–7 average, 0–3 weak. Altman: above 2.99 safe, 1.81–2.99 grey, below 1.81 distress. Our calculation can differ slightly from the provider's current scores above.

Liquidity

Can it meet short-term obligations?

Check whether cash and current assets cover what falls due within a year without depending on fresh financing.

Cash & Equivalents

$254.07M

Q4 2025

3Y -6.3%1Y -3.1%

Quick Ratio

6.6x

Q4 2025

Current Ratio

6.6x

Q4 2025

Cash Ratio

5.5x

Q4 2025

Working capital

How quickly does cash come back?

Receivable, inventory, and payable days show how much cash the operating cycle ties up and whether that is changing.

Working capital and cash conversion

Annual days measures from year-end receivables, inventory, and payables against revenue and cost of revenue.

Working capital (Q4 2025)

$258.71M

Current assets − current liabilities

Days sales outstanding

637 days

-339 days vs prior year

Days inventory outstanding

0 days

+0 days vs prior year

Days payables outstanding

334 days

-230 days vs prior year

Cash conversion cycle

303 days

-108 days vs prior year

Leverage

How much debt risk sits on the balance sheet?

Review total borrowings, debt relative to equity and assets, and whether operating profit covers interest costs.

Total Debt

$19.76M

Q4 2025

3Y -10.2%1Y -6.3%

Debt/Equity

0.1x

Q4 2025

Debt/Assets

0.0x

Q4 2025

Interest Coverage

—

Q4 2025

Debt service

Can cash flow carry the debt?

Measure debt against EBITDA and free cash flow, see how much is due within 12 months, and follow debt and cash over time.

Debt service capacity

Can operating cash flow carry the debt, and how much is due soon?

Net debt

Net cash $259.14M

Total debt − cash − short-term investments

Net debt / EBITDA

Net cash

Above 3× is elevated

Free cash flow / debt

-431.9%

Share of debt one year of FCF could repay

Years to repay debt

FCF negative

Total debt ÷ free cash flow

Operating cash flow / current liabilities

-1.8×

Above 1× funds a year of obligations

Interest coverage

-2.2×

Operating income ÷ interest expense

Debt maturity

Cash and short-term investments cover short-term debt 56.7×

Due within 12 months$4.92MDue later$0

Balance sheet as of Q4 2025; cash flows FY 2025.

Debt and cash over time

Fiscal-year-end borrowings against liquid assets; net debt below zero means net cash.

Balance sheet cushion

How much room is there if conditions weaken?

Extra cash and investments, and the balance of assets against liabilities, give the company room when trading gets harder.

Long-Term Investments

$217.43M

Q4 2025

3Y +68.8%1Y +11.8%

Assets

$534.71M

Q4 2025

3Y -2.7%1Y -3.3%

Liabilities

$229.03M

Q4 2025

3Y -5.8%1Y +24.3%

Balance sheet quality

Who funds the assets, and how tangible is the equity?

Split the claims on assets between suppliers, lenders, customers, and shareholders, and see how much equity rests on goodwill and intangibles.

Balance sheet quality

Who funds the assets, and how much of the equity is tangible (Q4 2025).

Claims on $534.71M of assets

  • Payables0.6%
  • Short-term debt0.9%
  • Other liabilities41.3%
  • Equity57.2%

Goodwill + intangibles

$601K

0.1% of total assets

Share of equity

0.2%

Above 50% leaves little tangible backing

Tangible equity

$311.47M

Equity left after writing off goodwill and intangibles

Deferred revenue

$0

Customer prepayments: a liability settled by delivering service, not cash

Shareholder claims

What do shareholders take out of the cash?

Dilution, stock-based pay, dividends, and buybacks all draw on cash flow; check whether free cash flow funds them.

Shareholder claims on cash

Dilution, stock-based pay, and whether free cash flow funds what is returned to shareholders.

Diluted shares, yearly change

-39.3%

FY2020–FY2025 compound rate

Stock-based compensation

$8.22M

Dividends paid

None

FY 2025

Dividend / free cash flow

—

Above 100% means dividends exceed free cash flow

Buybacks

$2.06M

FY 2025

Weighted diluted shares outstanding

Competitor health

How does PureTech Health plc compare with peers?

Compare leverage, interest coverage, and liquidity ratios with similar companies.

Competitor Health

Peer financial health comparison

CompanyMarket CapD/ED/AssetsND/EBITDAInt. Cov.QuickCurrentCash

Alumis Inc.

ALMS:NASDAQ

$3.54B0.120.090.21—4.344.341.22

Solid Biosciences Inc.

SLDB:NASDAQ

$679.38M0.120.090.22—6.146.141.79

Neurogene Inc.

NGNE:NASDAQ

$589.58M0.040.031.08—16.5616.566.33

Autolus Therapeutics plc

AUTL:NASDAQ

$383.25M1.970.60Net cash—5.485.941.42

Rocket Pharmaceuticals, Inc.

RCKT:NASDAQ

$375.63M0.090.080.25—6.386.382.57

Benitec Biopharma Inc.

BNTC:NASDAQ

$335.44M0.010.012.34—54.6754.6754.24

Neumora Therapeutics, Inc. Common Stock

NMRA:NASDAQ

$298.31M0.000.000.78—5.875.875.62

Lineage Cell Therapeutics, Inc.

LCTX:AMEX

$289.19M0.050.020.56—5.205.203.59

ADC Therapeutics S.A.

ADCT:NYSE

$171.71M-2.361.36Net cash—4.314.373.72

Quantum-Si incorporated

QSI:NASDAQ

$162.69M0.020.020.18—7.507.640.94

Questions

Financial health questions

Common questions about PRTC's balance sheet, answered from the reported figures.

Is PRTC's balance sheet healthy?

PureTech Health plc (PRTC) has a current ratio of 6.59, a quick read on short-term liquidity.

How leveraged is PRTC?

Debt to equity is 0.06, which helps judge how much financing risk sits on the balance sheet.